Israeli radiation therapy firm Alpha Tau raises $29 million

Alpha Tau Medical, an Israeli developer of alpha radiation cancer therapy, said on Wednesday it raised $29 million in a private financing round led by  private equity firm Shavit Capital.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

The physical and psychological side effects of breast cancer therapies can have substantial impact on survivors' physical and social functioning. Roughly half of the more than 3 million Americans alive with a history of breast cancer report adverse, function-degrading sequelae related to their oncologic treatments. Care delivery models for the timely delivery of rehabilitation services have been proposed yet limitedly vetted or implemented. These include the prospective surveillance model, procedure-linked referrals, survivorship care plans, and risk stratification. Patients' capacity to engage in the rehabilitative proces...
Source: American Journal of Physical Medicine and Rehabilitation - Category: Rehabilitation Tags: Literature Review Source Type: research
ConclusionsHere, we summarize current knowledge on microRNA-mediated redox regulatory mechanisms underlying chemo/radio-resistance. This knowledge may form a basis for a better clinical management of cancer patients.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Persistent fatigue at 1 year after EBRT in prostate cancer survivors is likely related to a cluster of symptoms elicited by chronic inflammation. Therapies that target each of these symptoms will likely reduce fatigue in this patient population.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
Abstract The growing incidence of cancer, the toxic side-effects associated with conventional chemotherapeutic agents and the development of multidrug resistance (MDR) drives the search for novel and more effective drugs with multi-target activity and selectivity towards cancer cells. Stilbenes are a group of naturally occurring phenolic compounds of plant origin derived from the phenylpropanoid pathway that may exist as cis- or trans-isomers. Although the trans-isomer is the more common and stable configuration, resveratrol being a representative compound, cis-stilbenes are potent cytotoxic agents that bind to an...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
We report the development of a biocompatible and bioactive material with desirable magnetic properties that show excellent hyperthermia properties and can be used for destruction of the cancerous tissue in addition to supporting tissue regeneration for treatment of bone tumors. In the current study, iron (Fe3+)-containing HT nanostructured material was prepared, and its biocompatibility, bioactivity, and hyperthermia abilities were studied. The developed materials showed effective hyperthermic properties with increased biocompatibility as compared to magnetite.Graphical abstract
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
CONCLUSIONS: Persistent fatigue at 1 year after EBRT in prostate cancer survivors is likely related to a cluster of symptoms elicited by chronic inflammation. Therapies that target each of these symptoms will likely reduce fatigue in this patient population. PMID: 30625479 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
Conclusion: Childhood cancer survivors present with unique challenges for dental management because of dental anomalies caused by cancer therapy. Interprofessional collaborative care between the pediatric dentist and the oncologist during and after cancer therapy will enable best outcomes for the pediatric patient. In addition, dental professionals must be prepared to meet the unique needs of long-term cancer survivors because of the increasing survival rates of childhood cancers. PMID: 30559620 [PubMed]
Source: Ochsner Journal - Category: General Medicine Tags: Ochsner J Source Type: research
The hypothalamic-pituitary-thyroid axis is a common site of unintended, acquired disease either during or after the treatment of cancer. Children treated with external radiation therapy are at the highest risk for developing a thyroid-related late effect, but thyroid dysfunction and second primary thyroid neoplasms can also occur after treatment with radiopharmaceutical agents such as131I-metaiodobenzylguanidine. Increasingly recognized is the development of early thyroid dysfunction as an off-target consequence of the more novel cancer therapeutics such as the tyrosine kinase inhibitors and immune checkpoint inhibitors. T...
Source: Hormone Research in Paediatrics - Category: Endocrinology Source Type: research
Abstract The application of modelling to solve problems in biology and medicine, and specifically in oncology and radiation therapy, is increasingly established and holds big promise. In this review, we provide an overview of the basic concepts of the field and its current state, along with new tools available and future directions for research. We will outline radiobiology models, examples of other anti cancer therapy models, multi-scale modelling and we will discuss the mechanistic and phenomenological approaches to modelling. PMID: 30485129 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research
This study evaluates contemporary rates of VTE in real world settings using this risk score.Methods: The Optum©'s Clinformatics® Data Mart database (01/01/2012 - 09/30/2017) was used to select adult patients with ≥1 hospitalizations or 2 outpatient medical claims with a cancer diagnosis (index date) who were initiated on cancer therapy (e.g., chemotherapy or radiation therapy) within 45 days of the index date. To be included in this study, patients were also required to meet the following criteria: (1) continuous eligibility for ≥6 months before the index date (baseline period), (2) no VTE event during the b...
Source: Blood - Category: Hematology Authors: Tags: 331. Pathophysiology of Thrombosis: Poster III Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Israel Health | Radiation Therapy